Who should attend?
This meeting is of interest to scientists from different fields of cancer research, such as cancer biology, molecular pathology, molecular oncology, cancer immunology, pharmacology, radiation biology and oncology, and medical oncology, as it will cover the multifaceted role of cell death in cancer ranging from basic mechanisms of cell death signalling and resistance, tumour microenvironment, tumour heterogeneity, and immune effects to target discovery and new therapy concepts. Given its translational character, the conference is of broad interest for basic, translational and clinical researchers as well as for companies. We will provide ample opportunities for early stage basic and translational cancer researchers and young medical oncologists to present their work to the international community and to meet experts in the field in an inspiring informal atmosphere to share research findings and to establish or strengthen collaborations.
Topics to be covered
The various modes of programmed cell death and their regulation, e.g. apoptosis, autophagy and necroptosis;
Cancer cell autonomous TRAIL-receptor signaling and cancer progression;
Ouroborous, autophagy and growth control;
The interplay of p53-mediated apoptosis and tumour suppression;
The protein interaction map of apoptosis and autophagy;
Autophaghy and cancer metabolism;
Importance and therapeutic exploitation of the cellular stress response, the ubiquitin proteasome system and cell death signalling for cancer therapy;
In vivo RNAi screening for the identification of new resistance mechanisms;
Precision cancer therapy targeting mitochondria;
New strategies to kill cancer stem cells;
Therapeutic targets in DNA repair;
Therapeutic reprograming of radiation-induced immune deviation in normal tissue responses.
This meeting is of interest to scientists from different fields of cancer research, such as cancer biology, molecular pathology, molecular oncology, cancer immunology, pharmacology, radiation biology and oncology, and medical oncology, as it will cover the multifaceted role of cell death in cancer ranging from basic mechanisms of cell death signalling and resistance, tumour microenvironment, tumour heterogeneity, and immune effects to target discovery and new therapy concepts. Given its translational character, the conference is of broad interest for basic, translational and clinical researchers as well as for companies. We will provide ample opportunities for early stage basic and translational cancer researchers and young medical oncologists to present their work to the international community and to meet experts in the field in an inspiring informal atmosphere to share research findings and to establish or strengthen collaborations.
Topics to be covered
The various modes of programmed cell death and their regulation, e.g. apoptosis, autophagy and necroptosis;
Cancer cell autonomous TRAIL-receptor signaling and cancer progression;
Ouroborous, autophagy and growth control;
The interplay of p53-mediated apoptosis and tumour suppression;
The protein interaction map of apoptosis and autophagy;
Autophaghy and cancer metabolism;
Importance and therapeutic exploitation of the cellular stress response, the ubiquitin proteasome system and cell death signalling for cancer therapy;
In vivo RNAi screening for the identification of new resistance mechanisms;
Precision cancer therapy targeting mitochondria;
New strategies to kill cancer stem cells;
Therapeutic targets in DNA repair;
Therapeutic reprograming of radiation-induced immune deviation in normal tissue responses.
